38 / 48
IRC-assessed cumulative incidence of
CNS progression
IRC-assessed cumulative incidence of
non-CNS progression without prior CNS
progression
Fist-line Brigatinib (ALTA-1L): CNS and non-CNS efficacy
Crizotinib (n=138)
Brigatinib (n=137)
Cumulative incidence of
CNS progression, %
0
10
20
30
15
12
9
Time, months
3
6
18
0
Cause-specific HR
for CNS progression=
0.30 (95% CI, 0.15-0.60)
ime to CNS progression (without prior
systemic progression) T, ITT population
Brigatinib
(n=137)
Crizotinib
(n=138)
Cumulative incidence rate, % (95% CI)
6 months
4.0 (1.5-8.5)
15.5 (9.9-22.3)
12 months
12.0 (6.4-19.5) 22.6 (15.2-31.0)
Cause-specific HR (95% CI)
0.30 (0.15-0.60); P<0.001
a
Brigatinib (n=137)
Crizotinib (n=138)
0
10
20
30
40
50
Cumulative incidence of
non-CNS progression, %
15
12
9
Time, months
3
6
18
0
Cause-specific HR for
non-CNS progression=
0.51 (95% CI, 0.30-0.86)
Time to non-CNS progression (without prior
CNS progression), ITT population
Brigatinib
(n=137)
Crizotinib
(n=138)
Cumulative incidence rate, % (95% CI)
6 months
12.6 (7.6-19.1)
20.0 (13.6-27.3)
12 months
20.2 (12.8-28.9)
36.8 (27.2-46.5)
Cause-specific HR (95% CI)
0.51 (0.30-0.86); P=0.017
a
Popat S, et al. Poster. ESMO. 2018 (abstr LBA58)